RU2010133847A - Терапевтические ингибиторы функции pai-1 и способы их применения - Google Patents

Терапевтические ингибиторы функции pai-1 и способы их применения Download PDF

Info

Publication number
RU2010133847A
RU2010133847A RU2010133847/10A RU2010133847A RU2010133847A RU 2010133847 A RU2010133847 A RU 2010133847A RU 2010133847/10 A RU2010133847/10 A RU 2010133847/10A RU 2010133847 A RU2010133847 A RU 2010133847A RU 2010133847 A RU2010133847 A RU 2010133847A
Authority
RU
Russia
Prior art keywords
amino acid
acid residues
acid residue
peptide
seq
Prior art date
Application number
RU2010133847/10A
Other languages
English (en)
Russian (ru)
Inventor
Томас Д. РИД (US)
Томас Д. РИД
Ричард И. ПЕТЕРСОН (US)
Ричард И. ПЕТЕРСОН
Чарльз С. РИД (US)
Чарльз С. РИД
СОПЧИНСКИ Джоан МАЗЗАРЕЛЛИ (US)
СОПЧИНСКИ Джоан МАЗЗАРЕЛЛИ
Бетани Л. МЕРЕНИК (US)
Бетани Л. МЕРЕНИК
Джонатан КАРСОН (US)
Джонатан КАРСОН
Кэтрин Л. БЭИР (US)
Кэтрин Л. БЭИР
Елена ТАШЕВА (US)
Елена ТАШЕВА
Original Assignee
Интрексон Корпорейшн (Us)
Интрексон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интрексон Корпорейшн (Us), Интрексон Корпорейшн filed Critical Интрексон Корпорейшн (Us)
Publication of RU2010133847A publication Critical patent/RU2010133847A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01099—Arabinan endo-1,5-alpha-L-arabinosidase (3.2.1.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2010133847/10A 2008-01-09 2009-01-09 Терапевтические ингибиторы функции pai-1 и способы их применения RU2010133847A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2013708P 2008-01-09 2008-01-09
US61/020,137 2008-01-09
US8064008P 2008-07-14 2008-07-14
US61/080,640 2008-07-14

Publications (1)

Publication Number Publication Date
RU2010133847A true RU2010133847A (ru) 2012-05-20

Family

ID=40853701

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010133847/10A RU2010133847A (ru) 2008-01-09 2009-01-09 Терапевтические ингибиторы функции pai-1 и способы их применения

Country Status (12)

Country Link
US (2) US8431363B2 (https=)
EP (1) EP2242501A4 (https=)
JP (2) JP2011509093A (https=)
KR (1) KR101712208B1 (https=)
CN (1) CN102123721A (https=)
AU (1) AU2009204464B2 (https=)
BR (1) BRPI0906867A2 (https=)
CA (1) CA2711878A1 (https=)
IL (1) IL206891A0 (https=)
MX (1) MX2010007586A (https=)
RU (1) RU2010133847A (https=)
WO (1) WO2009089059A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906867A2 (pt) 2008-01-09 2019-09-24 Intrexon Corp inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo
CN103154236B (zh) * 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
CN104271593B (zh) * 2012-05-01 2018-01-16 富士胶片株式会社 多能干细胞的培养方法及该方法中使用的多肽
CN103421781B (zh) * 2012-07-04 2014-12-31 华中农业大学 猪肌肉组织特异性表达基因myf6启动子及应用
KR20160089390A (ko) * 2013-12-10 2016-07-27 에프. 호프만-라 로슈 아게 다중-하부단위 구조에 대한 약학적 활성 개체의 표적화 전달을 위한 다중-하부단위 구조의 하부단위의 결합 도메인의 용도
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3123872A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
CN119656313B (zh) * 2024-12-13 2026-02-17 四川大学华西医院 Serpine1基因作为靶点在制备预防或治疗心肌纤维化药物中的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
AU1191001A (en) * 1999-10-07 2001-05-10 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
DE10053251A1 (de) * 2000-10-26 2002-05-08 Boehringer Ingelheim Pharma Epitope von PAI-1
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
US20030199463A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
US7785871B2 (en) 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
US20080050808A1 (en) * 2002-10-09 2008-02-28 Reed Thomas D DNA modular cloning vector plasmids and methods for their use
US7071295B2 (en) * 2002-12-02 2006-07-04 Intrexon Corporation Signal for targeting molecules to the sarco(endo)plasmic reticulum
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2007537755A (ja) 2004-05-18 2007-12-27 イントレクソン コーポレイション Ｄｎａクローニングベクタープラスミドのダイナミックなベクター構築のための方法
US8153598B2 (en) 2005-10-19 2012-04-10 Intrexon Corporation PKD ligands and polynucleotides encoding PKD ligands
WO2007048103A2 (en) 2006-10-18 2007-04-26 Intrexon Corporation Pkd ligands and polynucleotides encoding pkd ligands
US7943732B2 (en) * 2006-06-05 2011-05-17 Intrexon Corporation AKT ligands and polynucleotides encoding AKT ligands
US8993263B2 (en) * 2006-08-07 2015-03-31 Intrexon Corporation PKA ligands and polynucleotides encoding PKA ligands
US8999666B2 (en) * 2006-08-09 2015-04-07 Intrexon Corporation PKC ligands and polynucleotides encoding PKC ligands
US8283445B2 (en) * 2006-11-13 2012-10-09 Intrexon Corporation Extracellular-signal-regulated-kinase (ERK) heteropolyligand polypeptide
US8729225B2 (en) * 2006-11-13 2014-05-20 Intrexon Corporation Glycogen synthase kinase heteropolyligand polypeptide
US7705122B2 (en) * 2006-12-04 2010-04-27 Intrexon Corporation mTOR ligands and polynucleotides encoding mTOR ligands
EP2537924B1 (en) 2007-03-27 2015-03-18 Intrexon Corporation MEK ligands and polynucleotides encoding mek ligands
CA2722754A1 (en) * 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
BRPI0906867A2 (pt) 2008-01-09 2019-09-24 Intrexon Corp inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo

Also Published As

Publication number Publication date
US8431363B2 (en) 2013-04-30
US20130267022A1 (en) 2013-10-10
BRPI0906867A2 (pt) 2019-09-24
EP2242501A2 (en) 2010-10-27
AU2009204464A1 (en) 2009-07-16
CN102123721A (zh) 2011-07-13
EP2242501A4 (en) 2011-10-19
JP2011509093A (ja) 2011-03-24
US20110055940A1 (en) 2011-03-03
IL206891A0 (en) 2010-12-30
CA2711878A1 (en) 2009-07-16
JP2012135307A (ja) 2012-07-19
WO2009089059A2 (en) 2009-07-16
KR20100129271A (ko) 2010-12-08
WO2009089059A3 (en) 2009-09-24
KR101712208B1 (ko) 2017-03-03
MX2010007586A (es) 2011-02-22
AU2009204464B2 (en) 2014-12-04
US8828686B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
RU2010133847A (ru) Терапевтические ингибиторы функции pai-1 и способы их применения
Rucker et al. Elastin metabolism and chemistry: potential roles in lung development and structure
Vázquez et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity
Csiszar Lysyl oxidases: a novel multifunctional amine oxidase family
Chiquet-Ehrismann et al. Tenascins and the importance of adhesion modulation
Griendling et al. Molecular biology of the renin-angiotensin system.
Richards Genetic regulation of feed intake and energy balance in poultry
Panaro et al. Cellular responses to FMLP challenging: a mini-review
Osborne Williams–Beuren syndrome: unraveling the mysteries of a microdeletion disorder
Bicknell The tissue‐specific processing of pro‐opiomelanocortin
Poncelet et al. The transforming growth factor-βbgr/SMAD signaling pathway is present and functional in human mesangial cells
Karam et al. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: comparison with angiotensin-converting enzyme inhibition and calcium antagonism
Waller et al. Osteopontin in cardiovascular disease: a potential therapeutic target
Darras et al. Growth hormone acutely decreases type III iodothyronine deiodinase in chicken liver
Aikio et al. Specific collagen XVIII isoforms promote adipose tissue accrual via mechanisms determining adipocyte number and affect fat deposition
JP2011509093A5 (https=)
Rosenbloom [9] Elastin: an overview
JP3562528B2 (ja) Ｉｋａｒｏｓ：ｔ細胞経路調節遺伝子
EP1030916A2 (en) Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
He et al. Overexpression of Krueppel like factor 3 promotes subcutaneous adipocytes differentiation in goat Capra hircus
Tumselty et al. Adipocyte enhancer binding protein 1 and aortic carboxypeptidase-like protein
Shindo et al. Regulation of adrenomedullin and its family peptide by RAMP system–lessons from genetically engineered mice
Huang et al. Cloning of porcine chemerin, ChemR23 and GPR1 and their involvement in regulation of lipogenesis
Bergen et al. Topics in transcriptional control of lipid metabolism: from transcription factors to gene-promoter polymorphisms
Rourke et al. Characterization of the cholecystokinin and gastrin genes from the bullfrog, Rana catesbeiana: evolutionary conservation of primary and secondary sites of gene expression

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140811